Trimetazidine Dihydrochloride belongs to the class of other anti-anginal agents. It is indicated for the prophylactic treatment of angina pectoris, as well as for the symptomatic treatment of vertigo and tinnitus. It acts against adrenaline, noradrenaline, and vasopressin, reducing vascular resistance, increasing coronary and circulatory blood flow, and promoting myocardial metabolism and energy production. Additionally, it reduces myocardial oxygen consumption, thereby improving the balance between myocardial oxygen supply and demand. It also enhances the tolerance to cardiac glycosides.